首页> 外文学位 >Heterocycles in synthesis: Part I. Alpha,alpha-dialkylated amino acid derivatives via imidazoles. Part II. Approaches to the cyclopeptide alkaloids.
【24h】

Heterocycles in synthesis: Part I. Alpha,alpha-dialkylated amino acid derivatives via imidazoles. Part II. Approaches to the cyclopeptide alkaloids.

机译:合成中的杂环:第I部分。通过咪唑的α,α-二烷基化氨基酸衍生物。第二部分接近环肽生物碱。

获取原文
获取原文并翻译 | 示例

摘要

Part I. Improved preparations of N-hydroxy- and N-protio-2-4(5)-disubstituted imidazoles from olefins and nitriles are described. The products of subsequent N or O alkylation are exposed to singlet oxygen to afford N-alkylacylimines 48 and N-alkoxyacylimines 69 respectfully. Although both 48 and 69 are readily reduced with NaBH{dollar}sb4{dollar} to provide alpha-alkylated amino acid derivatives in essentially quantitative yield, 48 does not undergo 1,2-nucleophilic addition with organometallic reagents. In contrast 69 readily undergoes nucleophilic addition with a variety of organometallic reagents at {dollar}-78spcirc{dollar}C in THF to give alpha,alpha-dialkylated amino acid derivatives in good to excellent yields.; Part II. Two approaches to the cyclopeptide alkaloids employing either oxazoles or imidazoles as synthetic equivalents of the diamide/dipeptide segment are described.; In the first route, a general, highly efficient, nine step synthesis of novel oxazolophanes containing all the atoms of the 13- and 14-membered cyclopeptide alkaloid skeleton is achieved via an intramolecular macrocyclization of suitably substituted 5-acylaminooxazoles. The monomeric/dimeric nature of these oxazolophanes is not readily ascertained. The oxazolophanes are inert or unstable to all attempted deprotection/hydrolysis procedures. The search is in progress for a protecting group which allows cyclization of a linear precursor and undergoes mild removal to afford the cyclopeptide alkaloid system.; The second route details the progress made towards the elaboration of simple imidazoles into imidazolophanes, which upon exposure to singlet oxygen and base should provide the cyclopeptide alkaloid ring system. A general three step synthesis of 4(5)-substituted imidazoles has been improved. The {dollar}beta{dollar}-(trimethylsilyl)ethoxymethyl (SEM) group provides a general solution to imidazole N protection. SEM-imidazoles regio-specifically undergo C-2 metallation and subsequent reaction with a variety of electrophiles. Although 2-lithioimidazoles readily undergo 1,2-addition with BF{dollar}sb3cdot{dollar}Et{dollar}sb2{dollar}O activated simple imines, addition to 3-phenoxy-1-pyrrolines is not observed. BF{dollar}sb3cdot{dollar}Et{dollar}sb2{dollar}O promoted nucleopohilic addition to acyclic 3-phenoxyaldimines occurs, albeit low yields. Elaboration of a 1,2 addition product to a linear cyclization precursor is described. Cyclization studies aimed the construction of imidazolophanes are currently in progress.
机译:第一部分,描述了由烯烃和腈制备N-羟基-和N-protio-2-4(5)-二取代的咪唑的改进方法。将随后的N或O烷基化的产物暴露于单线态氧,以分别得到N-烷基酰基酰亚胺48和N-烷氧基酰基酰亚胺69。尽管用NaBH {sb4 {dollar}很容易还原48和69,从而以基本上定量的产率提供α-烷基化的氨基酸衍生物,但是48没有用有机金属试剂进行1,2-亲核加成。相反,在THF中,在69-78℃下,69容易与多种有机金属试剂进行亲核加成,从而以良好或优异的收率得到α,α-二烷基化的氨基酸衍生物。第二部分描述了两种使用恶唑或咪唑作为二酰胺/二肽链段的合成等同物的环肽生物碱的方法。在第一种途径中,通过分子内大环环化适当取代的5-酰基氨基恶唑,可以实现含有13和14元环肽生物碱骨架所有原子的新型恶唑烷的常规,高效,九步合成。这些草唑烷的单体/二聚体性质不容易确定。对于所有尝试的脱保护/水解过程,草唑烷都是惰性的或不稳定的。正在进行保护基团的搜索,该保护基团允许线性前体的环化并进行轻度去除以提供环肽生物碱系统。第二条路线详细说明了将简单的咪唑加工成咪唑并已获得的进展,该咪唑暴露于单线态氧和碱后应提供环肽生物碱环系统。一般的三步合成4(5)-取代的咪唑已得到改善。 {dol}β{dollar}-(三甲基甲硅烷基)乙氧基甲基(SEM)基团为咪唑N保护提供了一种通用解决方案。 SEM-咪唑区域特异性地进行C-2金属化,随后与各种亲电试剂反应。尽管2-硫代咪唑容易与BF {dollar} sb3cdot {dollar} Et {dollar} sb2 {dollar} O活化的简单亚胺进行1,2-加成,但未观察到除3-苯氧基-1-吡咯啉外。 BF {dollar} sb3cdot {dollar} Et {dollar} sb2 {dollar} O促进了核苷向无环3-苯氧基亚胺的加成,尽管收率很低。描述了将1,2加成产物精制为线性环化前体。目前正在进行针对咪唑烷的构建的环化研究。

著录项

  • 作者

    Vaccaro, Wayne David.;

  • 作者单位

    University of California, Santa Barbara.;

  • 授予单位 University of California, Santa Barbara.;
  • 学科 Chemistry Organic.
  • 学位 Ph.D.
  • 年度 1988
  • 页码 443 p.
  • 总页数 443
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 有机化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号